vs
Side-by-side financial comparison of Foghorn Therapeutics Inc. (FHTX) and Valens Semiconductor Ltd. (VLN). Click either name above to swap in a different company.
Valens Semiconductor Ltd. is the larger business by last-quarter revenue ($17.3M vs $9.2M, roughly 1.9× Foghorn Therapeutics Inc.). Valens Semiconductor Ltd. runs the higher net margin — -42.2% vs -234.3%, a 192.0% gap on every dollar of revenue. On growth, Foghorn Therapeutics Inc. posted the faster year-over-year revenue change (223.8% vs 8.1%).
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.
Valens Semiconductor (Valens) is an Israeli fabless manufacturing company providing semiconductors for the automotive and audio-video industries. Valens provides semiconductor products for the distribution of uncompressed ultra-high-definition (UHD) multimedia content and in-vehicle connectivity applications. The company is a member of the MIPI Alliance and developed the first-to-market chipset that is compliant with the MIPI A-PHY standard. Valens invented the technology behind the HDBaseT s...
FHTX vs VLN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.2M | $17.3M |
| Net Profit | $-21.7M | $-7.3M |
| Gross Margin | — | 63.0% |
| Operating Margin | -258.2% | -46.4% |
| Net Margin | -234.3% | -42.2% |
| Revenue YoY | 223.8% | 8.1% |
| Net Profit YoY | -11.1% | 29.3% |
| EPS (diluted) | $-0.35 | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.2M | — | ||
| Q3 25 | $8.2M | $17.3M | ||
| Q2 25 | $7.6M | $17.1M | ||
| Q1 25 | $6.0M | $16.8M | ||
| Q4 24 | $2.9M | — | ||
| Q3 24 | $7.8M | $16.0M | ||
| Q2 24 | $6.9M | $13.6M | ||
| Q1 24 | $5.0M | — |
| Q4 25 | $-21.7M | — | ||
| Q3 25 | $-15.8M | $-7.3M | ||
| Q2 25 | $-17.9M | $-7.2M | ||
| Q1 25 | $-18.8M | $-8.3M | ||
| Q4 24 | $-19.5M | — | ||
| Q3 24 | $-19.1M | $-10.4M | ||
| Q2 24 | $-23.0M | $-8.9M | ||
| Q1 24 | $-25.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 63.0% | ||
| Q2 25 | — | 63.5% | ||
| Q1 25 | — | 62.9% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.4% | ||
| Q2 24 | — | 61.4% | ||
| Q1 24 | — | — |
| Q4 25 | -258.2% | — | ||
| Q3 25 | -226.9% | -46.4% | ||
| Q2 25 | -279.2% | -43.3% | ||
| Q1 25 | -385.0% | -56.2% | ||
| Q4 24 | -840.5% | — | ||
| Q3 24 | -305.5% | -76.3% | ||
| Q2 24 | -386.6% | -69.2% | ||
| Q1 24 | -558.3% | — |
| Q4 25 | -234.3% | — | ||
| Q3 25 | -194.4% | -42.2% | ||
| Q2 25 | -237.3% | -42.1% | ||
| Q1 25 | -316.4% | -49.4% | ||
| Q4 24 | -682.9% | — | ||
| Q3 24 | -244.9% | -64.6% | ||
| Q2 24 | -333.6% | -65.2% | ||
| Q1 24 | -495.4% | — |
| Q4 25 | $-0.35 | — | ||
| Q3 25 | $-0.25 | $-0.07 | ||
| Q2 25 | $-0.28 | $-0.07 | ||
| Q1 25 | $-0.30 | $-0.08 | ||
| Q4 24 | $-0.23 | — | ||
| Q3 24 | $-0.31 | $-0.10 | ||
| Q2 24 | $-0.45 | $-0.08 | ||
| Q1 24 | $-0.59 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.9M | $93.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-108.5M | $108.8M |
| Total Assets | $198.1M | $136.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.9M | — | ||
| Q3 25 | $89.3M | $93.5M | ||
| Q2 25 | $72.6M | $102.7M | ||
| Q1 25 | $61.0M | $112.5M | ||
| Q4 24 | $55.5M | — | ||
| Q3 24 | $57.7M | $133.1M | ||
| Q2 24 | $138.9M | $105.9M | ||
| Q1 24 | $79.3M | — |
| Q4 25 | $-108.5M | — | ||
| Q3 25 | $-89.7M | $108.8M | ||
| Q2 25 | $-76.7M | $116.5M | ||
| Q1 25 | $-61.7M | $128.6M | ||
| Q4 24 | $-45.5M | — | ||
| Q3 24 | $-28.3M | $147.0M | ||
| Q2 24 | $-14.3M | $153.5M | ||
| Q1 24 | $-97.5M | — |
| Q4 25 | $198.1M | — | ||
| Q3 25 | $205.0M | $136.7M | ||
| Q2 25 | $226.2M | $144.8M | ||
| Q1 25 | $258.7M | $154.6M | ||
| Q4 24 | $284.0M | — | ||
| Q3 24 | $308.4M | $171.9M | ||
| Q2 24 | $328.6M | $175.8M | ||
| Q1 24 | $255.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-22.3M | $-4.7M |
| Free Cash FlowOCF − Capex | — | $-4.9M |
| FCF MarginFCF / Revenue | — | -28.5% |
| Capex IntensityCapex / Revenue | 0.0% | 1.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-11.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-22.3M | — | ||
| Q3 25 | $-18.9M | $-4.7M | ||
| Q2 25 | $-21.0M | $-211.0K | ||
| Q1 25 | $-24.0M | $-7.6M | ||
| Q4 24 | $-24.5M | — | ||
| Q3 24 | $-21.0M | $3.0M | ||
| Q2 24 | $-25.5M | $-225.0K | ||
| Q1 24 | $-29.3M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $-4.9M | ||
| Q2 25 | $-21.0M | $-330.0K | ||
| Q1 25 | $-24.0M | $-8.0M | ||
| Q4 24 | $-25.0M | — | ||
| Q3 24 | $-21.3M | $2.2M | ||
| Q2 24 | $-25.6M | $-460.0K | ||
| Q1 24 | $-29.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -28.5% | ||
| Q2 25 | -278.2% | -1.9% | ||
| Q1 25 | -403.2% | -47.3% | ||
| Q4 24 | -875.3% | — | ||
| Q3 24 | -273.0% | 14.0% | ||
| Q2 24 | -371.0% | -3.4% | ||
| Q1 24 | -583.1% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 1.6% | ||
| Q2 25 | 0.3% | 0.7% | ||
| Q1 25 | 0.5% | 2.1% | ||
| Q4 24 | 16.8% | — | ||
| Q3 24 | 4.0% | 4.5% | ||
| Q2 24 | 0.2% | 1.7% | ||
| Q1 24 | 2.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
